Physician profile
Mark Garbek
NPI 1679104624
$969.07
in general payments reported to CMS, 2019-2025
15 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.96 · 2022: $45.31 · 2023: $394 · 2024: $280 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $907.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $215.57 | 2023-2025 | |
| Ucb, INC. | $200.60 | 2022-2024 | Briviact, Fintepla |
| Gilead Sciences, INC. | $107.40 | 2022-2025 | Veklury |
| Janssen Pharmaceuticals, INC | $81.19 | 2023-2024 | Xarelto |
| Neurelis, INC. | $59.24 | 2023 | Valtoco |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.30 | 2023 | Jardiance |
| Paratek Pharmaceuticals, INC. | $42.01 | 2025 | Nuzyra |
| Boston Scientific Corporation | $35.05 | 2024-2025 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $30.61 | 2021-2024 | Eliquis |
| Actelion Pharmaceuticals US, INC. | $30.28 | 2023 | Uptravi, Opsumit |
| La Jolla Pharmaceutical Company | $29.45 | 2023-2024 | Xerava |
| Merck Sharp & Dohme LLC | $27.98 | 2023-2025 | Zerbaxa, Dificid, Recarbrio |
| Novo Nordisk INC | $26.45 | 2025 | Ozempic, Rybelsus |
| Scpharmaceuticals INC. | $23.03 | 2025 | |
| Abbvie INC. | $12.91 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Garbek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.